Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308976673> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4308976673 endingPage "vii107" @default.
- W4308976673 startingPage "vii107" @default.
- W4308976673 abstract "Abstract Inhibitors of Bruton’s tyrosine kinase (BTK) are approved treatments for several B cell lymphomas. However, they are characterized by modest selectivity and/or limited central nervous system (CNS) exposure which is important in instances of CNS disease. GB5121 is an orally available, selective, irreversible, covalent small molecule BTK inhibitor that was designed to address these limitations. Here, GB5121 was profiled for selectivity, potency, inactivation kinetics and CNS penetrance in comparison to ibrutinib. GB5121 pharmacodynamic properties were evaluated using both cell-free enzymatic and cell-based functional assays, showing nM potency for BTK inhibition and rapid BTK inactivation kinetics (Kinact/Ki) in both peripheral and CNS tissue, a critical parameter for irreversible inhibitors. In a kinome scan, GB5121 exhibited high kinase selectivity against 349 kinases with only TEC/TXK demonstrating > 50% inhibition at 1 µM; GB5121 did not inhibit phosphorylation of EGFR in a cell-based assay. When compared with other BTK inhibitors, GB5121 showed superior CNS target occupancy using a probe-based ELISA measuring free BTK in the brain of mice receiving 3 daily oral doses. GB5121 also demonstrated significantly higher brain to plasma ratio in mice with an intact blood brain barrier. In non-human primates, a 1:1 brain to plasma concentration ratio was demonstrated for GB5121 for up to 8 hours with both oral (30 mg/kg) and IV (2 mg/kg) doses. Together, these features differentiate GB5121 from both FDA-approved BTK inhibitors, as well as those currently under clinical investigation. Our data supports the use of GB5121 in clinical trials where BTK is a known driver of malignancies, including CNS lymphoma. This research has been previously presented at the AACR Annual Meeting 2022." @default.
- W4308976673 created "2022-11-20" @default.
- W4308976673 creator A5007369674 @default.
- W4308976673 creator A5012255396 @default.
- W4308976673 creator A5027382591 @default.
- W4308976673 creator A5035596475 @default.
- W4308976673 creator A5038297657 @default.
- W4308976673 creator A5039478407 @default.
- W4308976673 creator A5040898659 @default.
- W4308976673 creator A5046110842 @default.
- W4308976673 creator A5071899034 @default.
- W4308976673 creator A5088314635 @default.
- W4308976673 date "2022-11-01" @default.
- W4308976673 modified "2023-09-25" @default.
- W4308976673 title "DDDR-37. GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES" @default.
- W4308976673 doi "https://doi.org/10.1093/neuonc/noac209.402" @default.
- W4308976673 hasPublicationYear "2022" @default.
- W4308976673 type Work @default.
- W4308976673 citedByCount "0" @default.
- W4308976673 crossrefType "journal-article" @default.
- W4308976673 hasAuthorship W4308976673A5007369674 @default.
- W4308976673 hasAuthorship W4308976673A5012255396 @default.
- W4308976673 hasAuthorship W4308976673A5027382591 @default.
- W4308976673 hasAuthorship W4308976673A5035596475 @default.
- W4308976673 hasAuthorship W4308976673A5038297657 @default.
- W4308976673 hasAuthorship W4308976673A5039478407 @default.
- W4308976673 hasAuthorship W4308976673A5040898659 @default.
- W4308976673 hasAuthorship W4308976673A5046110842 @default.
- W4308976673 hasAuthorship W4308976673A5071899034 @default.
- W4308976673 hasAuthorship W4308976673A5088314635 @default.
- W4308976673 hasBestOaLocation W43089766731 @default.
- W4308976673 hasConcept C185592680 @default.
- W4308976673 hasConcept C202751555 @default.
- W4308976673 hasConcept C203014093 @default.
- W4308976673 hasConcept C2777938653 @default.
- W4308976673 hasConcept C2778461978 @default.
- W4308976673 hasConcept C2779878957 @default.
- W4308976673 hasConcept C42362537 @default.
- W4308976673 hasConcept C502942594 @default.
- W4308976673 hasConcept C55493867 @default.
- W4308976673 hasConcept C57992300 @default.
- W4308976673 hasConcept C62478195 @default.
- W4308976673 hasConcept C71924100 @default.
- W4308976673 hasConcept C90059517 @default.
- W4308976673 hasConcept C98274493 @default.
- W4308976673 hasConceptScore W4308976673C185592680 @default.
- W4308976673 hasConceptScore W4308976673C202751555 @default.
- W4308976673 hasConceptScore W4308976673C203014093 @default.
- W4308976673 hasConceptScore W4308976673C2777938653 @default.
- W4308976673 hasConceptScore W4308976673C2778461978 @default.
- W4308976673 hasConceptScore W4308976673C2779878957 @default.
- W4308976673 hasConceptScore W4308976673C42362537 @default.
- W4308976673 hasConceptScore W4308976673C502942594 @default.
- W4308976673 hasConceptScore W4308976673C55493867 @default.
- W4308976673 hasConceptScore W4308976673C57992300 @default.
- W4308976673 hasConceptScore W4308976673C62478195 @default.
- W4308976673 hasConceptScore W4308976673C71924100 @default.
- W4308976673 hasConceptScore W4308976673C90059517 @default.
- W4308976673 hasConceptScore W4308976673C98274493 @default.
- W4308976673 hasIssue "Supplement_7" @default.
- W4308976673 hasLocation W43089766731 @default.
- W4308976673 hasOpenAccess W4308976673 @default.
- W4308976673 hasPrimaryLocation W43089766731 @default.
- W4308976673 hasRelatedWork W1780111622 @default.
- W4308976673 hasRelatedWork W2015363069 @default.
- W4308976673 hasRelatedWork W2154945466 @default.
- W4308976673 hasRelatedWork W2172629347 @default.
- W4308976673 hasRelatedWork W2197292765 @default.
- W4308976673 hasRelatedWork W2521923968 @default.
- W4308976673 hasRelatedWork W2883892827 @default.
- W4308976673 hasRelatedWork W3086254297 @default.
- W4308976673 hasRelatedWork W3170106881 @default.
- W4308976673 hasRelatedWork W3210696086 @default.
- W4308976673 hasVolume "24" @default.
- W4308976673 isParatext "false" @default.
- W4308976673 isRetracted "false" @default.
- W4308976673 workType "article" @default.